Building Increased Production Capacity for Mucodyne
First written in FY2024-Q3. 2 of 4 entries say "Advanced", first in FY2025-H1. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「The Company is also working to further strengthen its stable supply system. At the Takaoka Plant, which began operations in April 2024, it is manufacturing generic drugs and Mucodyne Tablets, for which the authorities requested increased production, and made its first shipment in July.」
The system for increasing Mucodyne production progressed from the start of manufacturing at the Takaoka Plant to the first shipment in July 2024. - FY2025-H1AdvancedAnnual report
「The Company is also working to further strengthen its stable supply system. At the Takaoka Plant, which began operations in April 2024, the Company is manufacturing generic drugs and Mucodyne, for which the authorities requested increased production.」
The Takaoka Plant began operations in April 2024 and progressed to the stage of starting production of generic drugs and Mucodyne in response to a request for increased production. - FY2024RestatedAnnual report
「The Company will continue promoting the development of a system for increasing production of the product.」
For Mucodyne, the Company is continuing to build a system for increasing production following the increase in supply. - FY2024-Q3First statedAnnual report
「For Mucodyne, a drug that regulates airway mucosa and mucus, we increased supply in response in part to a request from the Ministry of Health, Labour and Welfare, and performance exceeded the prior-year level. We will continue to build an expanded production system for the product.」
Following an increase in Mucodyne supply in response to a request from the Ministry of Health, Labour and Welfare, the Group newly stated that it would continue building an expanded production system.